Orbactiv wiki
WebMar 14, 2024 · A Randomized, Open-label, PK and Safety Study to Evaluate the Relative Exposure and Safety of a New Formulation vs the Approved Formulation of a Single 1200 mg IV Dose of ORBACTIV® (Oritavancin) in Subjects Being Treated for ABSSSI: Actual Study Start Date : July 16, 2024: Actual Primary Completion Date : August 27, 2024: Actual Study ... WebFeb 22, 2024 · What Is Orbactiv? Orbactiv (oritavancin) for injection is an antibiotic used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus …
Orbactiv wiki
Did you know?
WebJul 7, 2024 · KIMYRSA™ (oritavancin) is a single-dose, long-acting lipoglycopeptide antibiotic with rapid bactericidal activity for the treatment of adult patients with ABSSSI caused by designated susceptible... WebSep 3, 2024 · ORBACTIV (oritavancin) for injection contains oritavancin diphosphate, a semisynthetic lipoglycopeptide antibacterial drug. The chemical name for oritavancin is …
WebFeb 25, 2024 · Orbactiv Dosage Generic name: ORITAVANCIN 400mg Dosage form: injection, powder, lyophilized, for solution Drug class: Glycopeptide antibiotics Medically reviewed by Drugs.com. Last updated on Feb 25, 2024. Dosage and Administration Overview There are two oritavancin products (ORBACTIV and KIMYRSA™, another oritavancin … Web2.2 Preparation of ORBACTIV for Intravenous Infusion . ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg …
WebJun 15, 2024 · Orbactiv. Generic name: oritavancin [ or-IT-a-VAN-sin ] Brand names: Kimyrsa, Orbactiv Drug class: Glycopeptide antibiotics. Medically reviewed by Drugs.com on Jun … WebUse ORBACTIV in patients on chronic warfarin therapy only when the benefits can be expected to outweigh the risk of bleeding. Frequently monitor for signs of bleeding. [see …
WebTo reduce the development of drug-resistant bacteria and maintain the effectiveness of oritavancin and other antibacterial drugs, oritavancin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
WebThe ORBACTIV® Assistance Program provides information about ORBACTIV® and about assistance that may be available to patients who meet certain criteria, including that they are not insured by a federal health care program. More information is available through the ORBACTIV® Assistance Program. gpts are gpts pdfWeb7 rows · Feb 20, 2014 · Brand name: Orbactiv. Generic name: oritavancin. Dosage form: Injection. Company: The Medicines Company. Treatment for: Skin and Structure Infection. … gpt schutzpartition usb adapterWebFeb 22, 2024 · Orbactiv IV is a prescription medicine used to treat the symptoms of Acute Bacterial Skin and Skin Structure Infections. Orbactiv IV may be used alone or with other medications. Orbactiv IV belongs to a class of drugs called Glycopeptides. It is not known if Orbactiv IV is safe and effective in children younger than 18 years of age. gpt sealsWebORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureu s (including methicillin-susceptible [MSSA] and -resistant [MRSA] … gpt seals staffordWebSep 3, 2024 · The empirical formula of oritavancin diphosphate is C86H97N10O26Cl3•2H3PO4 and the molecular weight is 1989.09. ORBACTIV is supplied as a sterile white to off-white lyophilized powder for intravenous infusion that contains oritavancin diphosphate, mannitol (an inactive ingredient) and phosphoric acid (to adjust … gpt secure bootgpts eduWebORBACTIV® (oritavancin): The first Single dose regimen for treating ABSSSI A single 1200 mg infusion helps ensure adherence to a full course of therapy. No dosing adjustment is required for 1: Mild-to-moderate renal impairment * Mild-to-moderate hepatic impairment † Weight Age (≥18 years of age) Gender Race gpt search bing